RE: Proff clive Page29 Sep 2023 09:05
This favourable biosynthetic shift from pro-inflammatory [lipid mediators] to inflammation-resolving SPM might be a plausible mode of action underlying the well-recognised anti-inflammatory properties of CBD and represents a molecular strategy to accomplish a local environment that is beneficial to promote inflammation resolution,’ they concluded.
Charles Serhan, an expert in infection and immunity at Harvard University in the US, describes the study as a ‘very important contribution’ as it brings together the cannabinoid field and the lipid mediators that play a role in the resolution of inflammation.
‘The group provides a mechanism for how the cannabinoids could evoke their well-known anti-inflammatory actions,’ he adds. ‘They clearly demonstrate that CBD switches off the pro-inflammatory mediators, the prostaglandins, produced by human M2 macrophages, and turns on the pro-resolving [mediators].’
But he said the ‘critical question’ was whether this can be demonstrated in a human trial. ‘A study like this will open the door for that possibility,’ he says.
Clive Page, an expert in the pharmacology of inflammation based at King’s College London, says it is increasingly recognised that CBD is not just a compound that affects cannabinoid receptors but has activity on a wide range of receptors.
‘The interesting thing [in this study] is that CBD is switching to the production of molecules that actually resolve the inflammation; that’s what happens physiologically…it’s when it doesn’t resolve that you end up with chronicity.’ Page agreed with Serhan that placebo-controlled trials of CBD in the clinic are now needed.
‘What we desperately need, and what is missing from the literature, is proper evidence in clinical trials…this paper effectively just adds more to the literature that we should be taking CBD seriously because, unlike THC from cannabis, it doesn’t have psychoactive effects and… it’s got a reasonable safety track record,’ Page adds. ‘What we’ve got to do is tease out the right dose for the right indication.’
Sign In
Follow the stocks
